Merck has made the decision to end 2 clinical trials evaluating its programmed death receptor-1 (PD-1)-blocking antibody, Keytruda ® (pembrolizumab).

Greater ability to function normally, greater reduction in activity limitations, and greater rate of satisfaction seen with medication ...

(HealthDay News) — Counties with high pharmacy desert densities also face social vulnerability and health care provider shortages, according to a research letter published online Aug. 23 in JAMA ...

Plexiform neurofibromas are tumors that grow in an infiltrative pattern along the peripheral nerve sheath, resulting in pain and functional impairment in patients with NF1.

Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no contraindications.

(HealthDay News) — Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study published online Aug. 23 in Alzheimer’s & Dementia.

Most psychedelics were better than placebo in psychedelic trials, but in antidepression trials of escitalopram, only high-dose psilocybin was better than placebo. (HealthDay News) — Patients treated ...

Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 messenger RNA.

High-intensity adopters had reduction in documentation for full postadoption periods and following learning period ...

Extensive binding of lecanemab to brain blood vessels observed in Down syndrome postmortem brain tissue analysis ...

As a summer surge in COVID cases begins to ebb and Americans brace themselves for yet another wave of infections this winter, more free COVID tests will soon be available to all.

Estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 vs dulaglutide among older adults.